Autopsy report · NCT01181921
The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease
Cause of deathSlow enrollment
“The recruitment rate was very low (one screening failure and one early withdrawal patient)”
Life of this trial
- Registered 9 months before it started.
- Ran for about 1 month before it stopped.
- 1 participant enrolled.
- Results were posted on the registry 1 year 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 4
- Sponsor
- Janssen-Cilag, S.A.
- Sponsor type
- Industry
- Conditions
- Alzheimer Disease
- Interventions
- Galantamine
- Participants
- 1
- Sites
- 1
- Countries
- Spain
Trials that died the same way
- Comparing Satisfaction With a Participatory Driven Web-application and a Standard Website
“The primary trial was stopped. Since, a feasibility study showed that recruitment was not feasible. We obtain a recruitment rate of 15 %.” - The Effect of Ovamax on Oocyte Quality
“The study was stopped prematurely due to low recruitment rate” - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.
“Low recruitment rate due to treatment regimen change” - Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults
“No more patients complying the selection criteria were available for recruitment” - Effects (Long Term Analysis) of an Hyperproteinic Nutrition on Neonates With Intra-uterine Growth Delay : a Prospective, Multicentric , Randomized, Double Blind Study ("Proneonat")
“difficulties of recruitment, high number of patients lost to follow-up”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.